[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cirrhoses-liver\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cirrhoses-liver":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,79,108,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100602165","prospexpo--study-of-the-associations-between-hepatocellular-carcinoma-and-chemical-and-psychosocial-environmental-exposome-100602165",false,"NCT07119957","ProspEXPO : Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome","ProspEXPO : PROSPective Study of the Associations Between Hepatocellular Carcinoma and Chemical and Psychosocial Environmental EXPOsome","ProspEXPO","Inclusion Criteria:\n\n* Presence of metabolic and\u002For alcoholic steatotic liver disease, as defined by the new nomenclature (MASLD, ALD, or mixed MetALD)\n* Liver biopsy performed (less than 2 months ago) or planned as part of treatment for diagnosis of cirrhosis (\"Control\" group without HCC) or diagnosis of HCC on cirrhosis (\"Case\" group)\n* Patient affiliated to or benefiting from a social security scheme\n* Patient having signed an informed consent to participate in the study (bio-collection)\n\nExclusion Criteria:\n\n* Causes of chronic liver disease other than MASLD, ALD, or MetALD\n* Decompensation of cirrhosis in the two years prior to inclusion (ascites, hepatic encephalopathy, gastrointestinal variceal hemorrhage, liver failure, hepatorenal syndrome)\n* For the \"Control\" group: history of hepatocellular carcinoma\n* Pregnant, breast-feeding or parturient women\n* Persons deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of the study is to build up a bio-collection of biological samples from patients with cirrhosis. Further work using this bio-collection will permit to describe the influence of different exposome factors (nutrition, physical activity, socio-demographic conditions, tobacco, alcohol, pollutants) on the occurrence of the main type of liver cancer (called HCC).\n\nIndeed, in the vast majority of cases, HCC develops within cirrhosis, and the factors that precipitate the progression of cirrhotic patients to HCC remain largely unknown.",[27,28],"Cirrhoses, Liver","Carcinoma Liver",[30,31,32],"Liver Cirrhosis","HepatoCellular Carcinoma (HCC)","Exposome","RECRUITING","2026-06-09",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2025-12-17",{"date":41,"type":21},"2029-03",{"name":43,"class":44},"University Hospital, Angers","OTHER_GOV",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100613489","phase-2-evaluating-the-efficacy-of-vonoprazan-in-preventing-post-endoscopic-variceal-band-ligation-ulcers-a-randomized-controlled-trial-100613489","NCT07267260","Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 75 years (male or female)\n* Diagnosis of liver cirrhosis confirmed by clinical, biochemical, or imaging findings.\n* Presence of documented esophageal varices requiring endoscopic variceal band ligation (EVBL).\n* Able and willing to provide written informed consent in English or Urdu.\n* Willing to comply with study procedures, including taking study medication and attending follow-up endoscopy.\n\nExclusion Criteria:\n\n* History of gastric or esophageal surgery\n* Allergy or contraindication to vonoprazan or study drug components\n* Pregnant or lactating women\n* Individuals who are non-cooperative or unable to understand local languages\n* Critically ill patients, including:\n\nICU admission Requirement for mechanical ventilation GCS \\\u003C 10\n\n* Active gastrointestinal bleeding at the time of enrollment\n* Malignancy of the upper gastrointestinal tract","75 Years",{"count":54,"type":21},154,[56],"PHASE2","The goal of this clinical trial is to learn if the medicine vonoprazan can help prevent ulcers that may develop after endoscopic variceal band ligation (EVBL) in adults with liver cirrhosis. These ulcers sometimes cause pain or delayed bleeding after the procedure.\n\nThe study will also look at how well vonoprazan is tolerated and if it improves comfort after the procedure.\n\nThe main questions this study will answer are:\n\nDoes vonoprazan lower the number and severity of ulcers found on endoscopy after EVBL?\n\nDoes vonoprazan reduce swallowing pain or chest discomfort compared with placebo?\n\nIs vonoprazan safe and well tolerated in people with liver cirrhosis?\n\nResearchers will compare vonoprazan 20 mg once daily with a placebo (a look-alike tablet that contains no active medicine) to see if vonoprazan works better to prevent these ulcers.\n\nParticipants will:\n\nTake vonoprazan or placebo by mouth once daily for 14 days after EVBL.\n\nReturn for a follow-up endoscopy about two weeks later to check for ulcers.\n\nReport any symptoms such as pain, nausea, or swallowing difficulty during the study.\n\nAdults aged 18 to 75 years with liver cirrhosis who undergo EVBL will be invited to join. Participants will be randomly assigned to one of two groups, and neither they nor the study doctors will know which treatment they receive (double-blind design).\n\nThe study will take place at Mayo Hospital, Lahore, Pakistan, over about six months.\n\nBy comparing vonoprazan to placebo, researchers hope to find a better way to protect the esophagus and stomach after EVBL, reduce post-procedure pain, and support faster recovery in people with liver cirrhosis.",[27],[60,61,62,63,64,65,66,67],"Vonoprazan","Potassium-competitive acid blocker","Endoscopic variceal band ligation","Esophageal varices","Post-procedure ulcer","Cirrhosis","Portal hypertension","Double-blind randomized controlled trial","2025-12-24",{"date":70,"type":37},"2025-12-26",{"date":72,"type":21},"2025-12-16",{"date":74,"type":21},"2026-03-05",{"name":76,"class":77},"King Edward Medical University","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":78},"100608739","laparoscopic-partial-splenectomy-for-hypersplenism-in-liver-cirrhosis-patients-100608739","NCT07205471","Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients","The Clinical Efficacy of Laparoscopic Partial Splenectomy for Hypersplenism in Liver Cirrhosis Patients","LPSH","Inclusion Criteria:\n\n* A clinical, radiological or histologic diagnosis of cirrhosis of any etiology\n* Splenomegaly with secondary hypersplenism\n* gastroesophageal variceal bleeding\n* Informed consent to participate in the study\n\nExclusion Criteria:\n\n* Hepatocellular carcinoma or any other malignancy,\n* Child-Pugh grade C\n* Recent peptic ulcer disease\n* History of Hemorrhagic stroke\n* Pregnancy.\n* Uncontrolled Hypertension\n* Human immunodeficiency virus (HIV) infection",{"count":88,"type":21},30,[24],"In this study,the researchers compared the changes in immune function-related indicators in patients with liver cirrhosis following laparoscopic partial splenectomy,to determine whether this surgical intervention can enhance postoperative immune function and thereby improve patient outcomes.",[27,92,93],"Splenectomy; Status","Partial",[65,95,96,97,98],"Splenectomy","Laparoscopy","immune function","partial","2025-09-25",{"date":101,"type":37},"2025-10-03",{"date":103,"type":37},"2025-09-24",{"date":105,"type":21},"2028-09-24",{"name":107,"class":77},"Northern Jiangsu People's Hospital",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":78},"100604490","study-on-proteomic-and-microbiome-changes-in-patients-with-hepatic-encephalopathy-he-100604490","NCT07150195","Study on Proteomic and Microbiome Changes in Patients With Hepatic Encephalopathy (HE)","Inclusion Criteria:\n\nFor the NHE (No Hepatic Encephalopathy) Group:\n\n1. Aged between 18 and 85 years, inclusive.\n2. Diagnosis of liver cirrhosis.\n3. Normal blood ammonia level.\n4. West-Haven Criteria grade 0 for Hepatic Encephalopathy.\n5. Normal neurological signs.\n6. Normal neuropsychological test results.\n7. Willing to participate and provides written informed consent.\n\nFor the CHE (Covert Hepatic Encephalopathy) Group:\n\n1. Aged between 18 and 85 years, inclusive.\n2. Diagnosis of liver cirrhosis.\n3. Elevated blood ammonia level.\n4. Diagnosis of Covert Hepatic Encephalopathy (West-Haven Criteria grade 0 or I).\n\n   * Grade 0: No personality or behavioral changes but abnormal neuropsychological tests.\n   * Grade I: Mild cognitive impairment, lack of awareness, euphoria or anxiety, shortened attention span, or impaired performance of addition\u002Fsubtraction.\n5. Neurological signs are normal or mild asterixis (flapping tremor) may be elicited.\n6. Neuropsychological tests are abnormal.\n7. Willing to participate and provides written informed consent.\n\nExclusion Criteria:\n\n1. Diagnosis of any malignant tumor.\n2. History of treatment for any malignant tumor.\n3. Presence of severe concomitant cardiac, pulmonary, cerebral, or renal diseases, or severe diabetic complications.\n4. Use of antibiotics, prebiotics, probiotics, or proton pump inhibitors within the three months prior to enrollment.\n5. Pregnancy, lactation, or puerperium.","85 Years",{"count":116,"type":21},32,"OBSERVATIONAL","The objective of this observational study is to compare the differences in proteomics and gut microbiome between the liver cirrhosis group without hepatic encephalopathy and the hepatic encephalopathy group through proteomics and microbiome analysis, screen out the characteristic proteomics and microbiome of patients with hepatic encephalopathy, guide clinical diagnosis and treatment, and conduct in-depth research on the pathogenesis of hepatic encephalopathy. The main questions it aims to answer are:\n\nAre there any differences in serum proteomes between patients with liver cirrhosis without hepatic encephalopathy and those with hepatic encephalopathy? If so, what are the main protein differences? There are differences in the fecal microbiome between patients with liver cirrhosis without hepatic encephalopathy and those with hepatic encephalopathy? If so, what are the main microbial differences?\n\nThis study will screen for the differences in proteomes and gut microbiomes between patients with liver cirrhosis without hepatic encephalopathy and those with hepatic encephalopathy, and identify the characteristic proteomes and microbiomes of patients with hepatic encephalopathy to guide clinical diagnosis and treatment.",[27,120],"Hepatic Encephalopathy (HE)","NOT_YET_RECRUITING","2025-09-23",{"date":99,"type":37},{"date":125,"type":21},"2025-09",{"date":127,"type":21},"2026-12",{"name":129,"class":77},"The First Affiliated Hospital with Nanjing Medical University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":140,"studyType":117,"phases":4,"briefSummary":141,"conditions":142,"keywords":159,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":45},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",true,{"count":139,"type":21},600,"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,27],"Cancer Diagnosis","Liver Cancer, Adult","Cancer Screening","Colorectal Cancer (CRC)","Gastric Cancers","Normal Physiology","Pancreatic Cancer, Adult","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Precancerous Conditions","Pancreatitis","Adenoma Colon Polyp","Gastric Ulcer","Oesophagitis",[160,161,145,150,162,163,164,152,165,166,155,167,168,158,169],"Pan-cancer","Deep Learning Models","Colorectal Cancer","Pancreatic Cancer","Gastric Cancer","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":172,"type":37},"2025-04-24",{"date":174,"type":37},"2022-09-01",{"date":176,"type":21},"2025-07-28",{"name":178,"class":77},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]